Eton Pharmaceutcials (ETON) Stock: Buy, Sell, or Hold?
ETON - Eton Pharmaceutcials, Inc. Common Stock
$54.75
2.77 (5.33%)
▲
5d:
-5.08%
30d:
-11.64%
90d:
+44.0%
HOLD
MODERATE Confidence
Analysis Updated: Oct 1, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When ETON Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ETON shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: ETON shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$91.44
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$56.78
3.6% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 18.2x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ETON is currently trading at $54.75, which is considered oversold relative to its 30-day fair value range of $55.35 to $61.46. From a valuation perspective, the stock is trading at a premium (Forward PE: 20.1) compared to its historical average (18.2). At these levels, the market is pricing in 3.4% annual earnings growth.
Technical Outlook: Technically, ETON is in a strong uptrend. Immediate support is located at $48.79, while resistance sits at $60.60. The stock is showing strong short-term momentum, up 5.3% recently.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $71.00 (+36.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ETON is in a strong uptrend. Immediate support is located at $48.79, while resistance sits at $60.60. The stock is showing strong short-term momentum, up 5.3% recently.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $71.00 (+36.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$55.35 -
$61.46
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
87.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.3%)
- BULLISH: Trading 36.6% below Wall St target ($71.00)
- BULLISH: Expecting earnings turnaround to 3.4% growth with 98.6% revenue growth
- NEUTRAL: Bottoming setup forming (40/100) — watch for confirmation
- CAUTION: 5-day price weakness (-5.1%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$55.35 -
$61.46
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$48.79
Resistance Level
$60.60
Current Trend
Strong Uptrend
Technical data as of
Oct 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
20.15
Wall Street Target
$71.00
(+36.6%)
Revenue Growth (YoY)
98.6%
Earnings Growth (YoY)
-12.6%
Profit Margin
12.0%
Valuation Premium vs History
+3.4% premium
PE vs Historical
20.2 vs 18.2
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+3.4%
(market-implied from PE analysis)
1-Year Target
$53.75
(+3%)
2-Year Target
$55.57
(+7%)
3-Year Target
$57.46
(+11%)
3-Yr Target (if PE normalizes)
(PE: 20→18)
PE COMPRESSION
$51.91
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.4, Growth: 84.3%)
$177.63
(+242%)
Base:
(SPY PE: 20.1, Growth: 84.3%)
$175.43
(+238%)
Bear:
(PE: 17.1, Growth: 84.3%)
$149.12
(+187%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (24x PE), but valuation improves significantly next year (20x PE) as earnings recover.
Forward PE: 23.92 | Forward EPS (Implied): $2.17
Bull Case
$62.77
(+21%)
Analyst growth 15.0%, PE expands to 25.1
Base Case
$51.98
(0%)
Market implied 0.0%, PE stable at 23.9
Bear Case
$39.76
(-24%)
Severe decline -15.0%, PE contracts to 21.5
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: October 02, 2026 10:22 AM ET
Data refreshes hourly during market hours. Next update: 11:22 AM
Data refreshes hourly during market hours. Next update: 11:22 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ETON showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$208 | 54 HOLD |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$96 | 58 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 55 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 62 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 53 HOLD |
